CITF & International Research Synthesis

People infected with SARS-CoV-2 can experience a wide range of outcomes, ranging from asymptomatic infection to severe disease and death.

The proportion of people in the U.S. with SARS-CoV-2 antibodies remains uncertain. A new study published in JAMA used a sample of 1.44 million blood samples from July 2020 through May 2021 to estimate the SARS-CoV-2 seroprevalence in the general US population aged 16 years and older.

The World Health Organization (WHO) has recently introduced a new Variant of Interest (VOI) titled Mu or B.1.621.

A recent state-of-the-art review in Nature Microbiology summarizes the latest evidence regarding the molecules in our cells that allow SARS-CoV-2 to infect us and how these may give us clues to discover new anti-viral drugs.

The field of public health has never been without critics. Globally, public health officers wield varying amounts of power, with the North American court systems historically respecting and upholding public health order.

Previous studies have shown that children with COVID-19 generally have a milder disease course compared to adults.

New research out of England published in The Lancet Infectious Diseases suggests that hospitalization and visits to the emergency department are twice as likely with the variant of concern (VOC) Delta compared to the Alpha variant.

While countries around the world are working to get their populations vaccinated, the emergence of SARS-CoV-2 variants of concern (VOCs) has threatened our return to normalcy.

As the world – and Canada – deals with increasing case numbers due to variants, scientists from the Imperial College London provide a snapshot of emerging data on real-life efficacy of COVID-19 vaccines against variants.